COMPANIES.- Promoting access to health through innovation, a strong commitment to caring for the environment, ensuring the well-being of its collaborators and communities, in addition to achieving permanent growth and international consolidation, are the key objectives of Eurofarma that is stand out in its 2023 Sustainability Report.
The pharmaceutical multinational, present in 22 countries, currently has a workforce of 12,600 employees. During last year, the company produced a total of 573 million units in its 11 plants, distributed in more than 2 thousand products, which reflects its mission based on promoting access to health and quality of life for people in all over the world, through sustainable and innovative development.
The 2023 Sustainability Report examines the progress made by the company in a 5-year cycle, guided by Vision 2027 that defines main objectives based on the digital transformation of health and being a leading player in sustainability.
At the same time, it emphasizes the company’s concern for creating quality health, especially in the most vulnerable areas of the region, with a clear purpose: Making health accessible so that everyone can live longer and better and in a healthy environment.
Proof of the above is that during 2023, it allocated RS$ 107 million (USD 21.7 million) to environmental and social initiatives, including diversity and inclusion programs, in addition to renewable energy and corporate social responsibility projects. (https://eurofarma.com/cartilla-sostenible https://eurofarma.com/cartilla-sostenible).
During the last 15 years, Eurofarma registered an average growth of 17% and in 2022 it began its activities in the United States, entering a market of great interest. It also consolidated a new stage in its governance structure, transforming into an open capital company.
It should be noted that the aforementioned report also highlights operational eco-efficiency, maintaining the traceability of its entire production chain, from its generation to the final destination and, above all, its optimal relations with society and communities, with significant investments to address in the best way to the most vulnerable people.
At the same time, and considering that advances in health – with better digital tools – must go beyond the mere development of medicines to achieve a true transformation, the Research and Development (R&D) area of Eurofarma has focused its I work on finding innovative medicines.
Finally, an important milestone is that for 19 years it has been among the best companies to work for in Brazil, providing a diverse, respectful and welcoming environment to its collaborators. Equity, diversity, inclusion and merit for work are values propagated in every sense. Internal climate surveys indicate that 85% of employees are proud to belong to the company, occupying leading positions in the regional and local Great Place to Work (GPTW) rankings.
